(22 March, 2017 Shanghai) Fosun Pharma recently conducted the signing ceremony for its majority investment in Breas at the head office of Breas in Mölnlycke. Executives of Fosun Pharma and PBM Capital, representatives of the city of Gothenburg and Business Region Gothenburg, as well as the entire Breas staff in Sweden, attended the event. Richard Zhao, Senior Vice President of Fosun Pharma’s Medical Device Department and Damian deGoa, the representative of PBM Capital, signed the agreements to formalize the partnership and to express their confidence in the bright future of Breas.

After the transaction, Fosun Pharma is now the majority owner of Breas, while PBM Capital remains engaged in the company with a minority share. Both partners are committed to supporting the growth of Breas and to bringing the company to the next level on a bigger global scale.

“With superb quality and services, the respiratory devices of Breas have already established a good reputation and served a wide range of customers”, remarked Richard Zhao, “We have firm faith in the management team of Breas and give high regards to the Swedish corporate culture of mutual cooperation and support. Amid active cooperation among veteran respiratory experts from Fosun Pharma and the management team of Breas, we’re convinced that Breas will capture a larger market share in the rapidly growing market of China.”

Damian deGoa says: “We will continue to execute our strategy and 2017 will be an exciting year. This year, we will launch many new products, including a family of world class home mechanical ventilation devices, new sleep apnea devices, a new airway clearance device, and an advanced cloud system for remote patient monitoring. We are investing into our rapidly expanding business in the USA and Fosun Pharma can offer a vast amount of knowledge, market expertise and focus in China, which is a huge opportunity for us. Moreover, Fosun Pharma is a global company with strong financial resources which will help drive Breas’ global expansion. ”

Besides, Fosun Pharma highly recognizes the importance and strength of the Breas team as one of the major reasons to invest in the company. The current Breas team will continue to be responsible to serve customers, clinicians, homecare providers and patients around the world. The company will continue to be known as and branded as Breas. By joining hands with Fosun Pharma, Breas will be able to accelerate its step in becoming the leader in home mechanical ventilation.

David Ljung, Chairman and Chief of Staff of Gothenburg Municipal Executive Committee, also delivered his congratulatory message, “Fosun Pharma’s acquisition of Breas is another milestone of Sino-Sweden business cooperation. We look forward to seeing Fosun Pharma bring resources and make Breas a more successful global medical enterprise.”

Fosun Pharma has been providing innovative solutions for patients suffering from respiratory diseases through its business platform and professional channels. This acquisition is Fosun Pharma’s another milestone in exploring Respiratory Medical field and diversifying its product lines. Upon completion of the transaction, a strategic platform covering from early-stage diagnosis of lung cancer and asthma to treatment device products for common respiratory diseases will be established to form a closed circuit for Fosun Pharma’s respiratory medical business.

About Breas Medical

Breas Medical was founded in 1991 in Mölnlycke, Sweden, as an entrepreneurial company that quickly developed to become one of the global leaders in home mechanical ventilation and sleep treatment. Breas successfully markets the Vivo and iSleep product ranges, the Nippy and Clearway brands,and the Z1 CPAP range, redefining CPAP use in terms of size, weight, and portability.

Breas is a global company selling in more than 40 countries through a network of subsidiaries (Sweden, UK, Spain, Germany, USA) and highly specialized distributors. The 150 Breas employees are the backbone of the company.  The employees share their passion for patients and customers which shows in how they approach customer service, product development, manufacturing, sales, marketing, quality and service. 

About Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare Group in the PRC. Fosun Pharma strategically covers important segments of the healthcare industry value-chain, including pharmaceutical manufacturing and R&D, healthcare services, medical diagnosis, medical devices manufacturing and agent, as well as pharmaceutical distribution and retail, making contribution to improving people’s health. Fosun Pharma maintains a National Recognized Enterprise Technology Centre and a highly capable international R&D team, focusing on innovation and research of therapeutic areas including cardiovascular system, central nervous system, blood system, metabolism and alimentary system, anti-infection and anti-tumor. With its commitment to innovation for good health and creating a better future, Fosun Pharma will continue insisting on the strategic development approach of “organic growth , external expansion and integrated development”, striving to be one of the leading enterprises in the global healthcare market.